Fluoroquinolones and the Risk for Methicillin-resistant Staphylococcus aureus in Hospitalized Patients

Emerging Infectious Diseases

Volumn 9, Issue 11, 2003, Pages 1415-1422

  Weber, Stephen G ^a,c   Gold, Howard S ^a   Hooper, David C ^b   Karchmer, A W ^a   Carmeli, Yehuda ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; LEVOFLOXACIN; METICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTCOMES RESEARCH; RISK FACTOR;

EID: 0242355075     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0911.030284     Document Type: Conference Paper

References (28)

1. Barrett FF, McGehee RF Jr, Finland M. Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations. N Engl J Med 1968;279:441-8.
2. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-42.
3. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001;39:3727-32.
4. Herold BC, Immergluck LC, Maranan MC, Lauderdal DS, Gaskin RE, Boyle-Vavra S, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-8.
5. Naimi TS, LeDell KH, Boxrud DJ, Groom AV, Steward CD, Johnson SK, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001;33:990-6.
6. Tenover FC. Development and spread of bacterial resistance to antimicrobial agents: an overview. Clin Infect Dis 2001;33:S108-15.
7. Mulligan ME, Ruane PJ, Johnston L, Wong P, Wheelock JP, MacDonald K, et al. Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am J Med 1987;82:215-9.
8. Harnett N, Brown S, Krishnan C. Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, Canada. Antimicrob Agents Chemother 1991;35:1911-3.
9. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32 Suppl 2:S114-32.
10. Crowcroft NS, Ronveaux O, Monnet DL, Mertens R. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999;20:31-6.
11. Dziekan G, Hahn A, Thune K, Schwarzer G, Schafer K, Daschner FD, et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J Hosp Infect 2000;46:263-70.
12. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002;49:999-1005.
13. Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000;31:1380-5.
14. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol 1992;135:1029-41.
15. Kaye KS, Harris AD, Gold H, Carmeli Y. Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients. Antimicrob Agents Chemother 2000;44:1004-9.
16. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 2002;34:1558-63.
17. Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis 2001;33:1462-8.
18. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001;45:2628-30.
19. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001;32:1055-61
20. Harris AD, Samore MH, Carmeli Y. Control group selection is an important but neglected issue in studies of antibiotic resistance. Ann Intern Med 2000;133:159.
21. Paterson DL. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis 2002;34:1564-7.
22. Schwaber MJ, Wright SB, Carmeli Y, Venkataraman L, DeGirolami PC, Gramatikova A, et al. Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis 2003;9:657-64.
23. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997;24(Suppl 1):S67-73.
24. Venezia RA, Domaracki BE, Evans AM, Preston KE, Graffunder EM. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother 2001;48:375-81.
25. Bisognano C, Vaudaux PE, Lew DP, Ng EY, Hooper DC. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 1997;41:906-13.
26. Bisognano C, Vaudaux P, Rohner P, Lew DP, Hooper DC. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 2000;44:1428-37.
27. Bisognano C, Kelly WL, Francois P, Schrenzel J, Lew DP, Hooper DC. Impact of agr and sar mutations on fibronectin-binding protein expression in quinolone-resistant (QR) Staphylococcus aureus exposed to sub-MIC levels of ciprofloxacin. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, Illinois; 2001 Dec 16-19; Abstract C1-651. Washington: American Society for Microbiology; 2001.
28. Bisognano C, Kelley WL, Francois P, Schrenzel J, Lew DP, Hooper DC, et al. Contribution of the SOS induction system to upregulation of fibronectin-binding proteins in quinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, California; 2001 Sep 27-30; Abstract C1-1063. Washington: American Society for Microbiology; 2002.